Evinova Enters into Collaboration with Bristol Myers Squibb to Improve Clinical Development Using Artificial Intelligence
Tuesday, February 10, 2026
Evinova has entered into a strategic collaboration with Bristol Myers Squibb to support more efficient and data-driven clinical development through artificial intelligence.
As part of the agreement, Bristol Myers Squibb will use Evinova’s AI-based Study Designer platform, specifically the Cost Optimizer module, across its global clinical trial portfolio.
The collaboration aims to improve decision-making in trial planning by using advanced AI to analyse study designs, identify productivity opportunities and reduce unnecessary complexity. The approach is intended to support more efficient trials, shorten development timelines and improve the experience for both clinical sites and patients.
Evinova’s clinical development platform is built with AI at its core and is designed to support collaboration across teams while enabling consistent digital data flow in line with USDM standards. The platform includes governance controls to support the responsible use of AI in clinical research and has been deployed at scale across multiple global programmes. According to the company, its solutions have contributed to significant long-term cost savings in clinical development.
Alongside trial design and optimisation tools, Evinova also offers a Unified Trial Solution that brings together key study components into a connected digital environment. This solution integrates electronic clinical outcome assessments with telehealth services and connected devices to support remote patient monitoring. The aim is to reduce operational friction, improve data capture for new endpoints and support more flexible trial designs.
Evinova’s products are developed using a human-centred design approach, incorporating feedback from patients and trial site teams. This has contributed to high levels of user engagement and strong compliance with digital assessment tools.
Overall, the collaboration reflects a broader industry shift towards the use of digital tools and artificial intelligence to improve clinical development efficiency, reduce costs and enhance patient outcomes.
Source: evinova.com
